Literature DB >> 35622329

Gene Engineering T Cells with T-Cell Receptor for Adoptive Therapy.

Dian Kortleve1, Mandy van Brakel2, Rebecca Wijers2, Reno Debets2, Dora Hammerl2.   

Abstract

Prior to clinical testing of adoptive T-cell therapy with T-cell receptor (TCR)-engineered T cells, TCRs need to be retrieved, annotated, gene-transferred, and extensively tested in vitro to accurately assess specificity and sensitivity of target recognition. Here, we present a fundamental series of protocols that cover critical preclinical parameters, thereby enabling the selection of candidate TCRs for clinical testing.
© 2022. The Author(s).

Entities:  

Keywords:  Gene transfer; In vitro assays; Sensitivity; Specificity; T-cell engineering; T-cell receptor; TCR annotation; TCR cloning

Mesh:

Substances:

Year:  2022        PMID: 35622329     DOI: 10.1007/978-1-0716-2115-8_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  17 in total

1.  IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.

Authors:  Nicoletta Cieri; Barbara Camisa; Fabienne Cocchiarella; Mattia Forcato; Giacomo Oliveira; Elena Provasi; Attilio Bondanza; Claudio Bordignon; Jacopo Peccatori; Fabio Ciceri; Maria Teresa Lupo-Stanghellini; Fulvio Mavilio; Anna Mondino; Silvio Bicciato; Alessandra Recchia; Chiara Bonini
Journal:  Blood       Date:  2012-11-15       Impact factor: 22.113

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.

Authors:  C H J Lamers; R A Willemsen; P van Elzakker; B A van Krimpen; J W Gratama; R Debets
Journal:  Cancer Gene Ther       Date:  2006-05       Impact factor: 5.987

4.  Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells.

Authors:  Matthias Wölfl; Philip D Greenberg
Journal:  Nat Protoc       Date:  2014-03-27       Impact factor: 13.491

5.  T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.

Authors:  Cor H J Lamers; Sabine van Steenbergen-Langeveld; Mandy van Brakel; Corrien M Groot-van Ruijven; Pascal M M L van Elzakker; Brigitte van Krimpen; Stefan Sleijfer; Reno Debets
Journal:  Hum Gene Ther Methods       Date:  2014-12       Impact factor: 2.396

6.  Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells.

Authors:  H Hanenberg; K Hashino; H Konishi; R A Hock; I Kato; D A Williams
Journal:  Hum Gene Ther       Date:  1997-12-10       Impact factor: 5.695

7.  Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor.

Authors:  K H Grabstein; J Eisenman; K Shanebeck; C Rauch; S Srinivasan; V Fung; C Beers; J Richardson; M A Schoenborn; M Ahdieh
Journal:  Science       Date:  1994-05-13       Impact factor: 47.728

Review 8.  TCR-engineered T cells to treat tumors: Seeing but not touching?

Authors:  Reno Debets; Emmanuel Donnadieu; Salem Chouaib; George Coukos
Journal:  Semin Immunol       Date:  2016-03-17       Impact factor: 11.130

9.  High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice.

Authors:  Jin Hee Kim; Sang-Rok Lee; Li-Hua Li; Hye-Jeong Park; Jeong-Hoh Park; Kwang Youl Lee; Myeong-Kyu Kim; Boo Ahn Shin; Seok-Yong Choi
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  T-cell libraries allow simple parallel generation of multiple peptide-specific human T-cell clones.

Authors:  Sarah M Theaker; Cristina Rius; Alexander Greenshields-Watson; Angharad Lloyd; Andrew Trimby; Anna Fuller; John J Miles; David K Cole; Mark Peakman; Andrew K Sewell; Garry Dolton
Journal:  J Immunol Methods       Date:  2016-01-28       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.